While most prenatal guidance promotes 400 micrograms of folic acid once pregnancy is confirmed, this generic advice arrives too late for one high-risk group: women managing epilepsy with antiseizure medications (ASMs). The 2026 SCAN-AED study, published in the Journal of Neurology, Neurosurgery & Psychiatry, delivers compelling evidence that initiating high-dose folic acid (typically 4-5 mg) in the 1-12 weeks before conception is associated with a 45% relative reduction in major congenital anomalies. In this nationwide register-based cohort of 13,000+ pregnancies from four Nordic countries, absolute risk fell from 48 to 26 cases per 1,000 births. The benefit was even more pronounced (up to 86% relative reduction) among users of high-teratogen drugs such as valproate.

This was an observational study employing target trial emulation to reduce bias, not an RCT; therefore residual confounding from health-seeking behavior or unmeasured socioeconomic factors remains possible. No conflicts of interest were declared. Its methodological strength and large sample size nevertheless address prior inconsistencies in the literature on folic acid timing for this population.

Mainstream coverage, including the MedicalXpress summary, correctly highlights the importance of pre-pregnancy initiation yet misses the deeper systemic pattern: women with chronic conditions are routinely sidelined by one-size-fits-all obstetric protocols. Neural tube closure is complete by day 28 post-conception, frequently before pregnancy is recognized. Valproate and certain other ASMs interfere with folate metabolism and transport, elevating risks of neural tube defects, cardiac malformations, and craniofacial anomalies. Starting supplementation after conception therefore shows no protective association in the SCAN-AED data, a crucial nuance that general prenatal campaigns rarely emphasize with sufficient urgency.

Synthesizing this with earlier landmark research strengthens the case. The 1991 MRC Vitamin Study (Lancet), a randomized controlled trial involving 1,817 women with prior neural tube defect pregnancies, demonstrated that 4 mg daily folic acid produced a 72% protective effect when taken periconceptionally. Similarly, data from the North American AED Pregnancy Registry (Hernández-Díaz et al., Neurology 2012; n≈5,000) documented markedly elevated malformation rates with valproate and carbamazepine, yet stopped short of quantifying the precise timing benefit now clarified by SCAN-AED. Together these sources reveal a consistent but previously fragmented story: dose, timing, and population-specific risk must align.

The editorial lens here is clear. This represents an actionable, pennies-per-day intervention for a vulnerable population whose needs are chronically overlooked. Epilepsy affects approximately 1 in 200 pregnancies; these women experience higher rates of unplanned pregnancy due to drug-contraceptive interactions, fragmented neurology-obstetrics communication, and socioeconomic barriers. Standard CDC folic acid messaging (0.4 mg) is insufficient for ASM users, yet few electronic health record systems or routine visits trigger tailored preconception counseling. The SCAN-AED findings therefore expose a preventable care gap rather than merely an individual supplementation issue.

Implementation challenges remain. Neurologists must initiate high-dose folic acid discussions at every visit with reproductive-age patients rather than deferring to obstetricians. Guidelines from the American Academy of Neurology already recommend avoiding valproate in pregnancy when possible, favoring lamotrigine or levetiracetam; the new evidence adds a parallel low-cost hedge for those who remain on higher-risk regimens. While the study rightly cautions against unilateral medication changes, it underscores that pregnancy planning must become standard neurologic practice.

In an era of precision public health, SCAN-AED illustrates how rigorous observational research on timing can deliver outsized impact. By connecting the periconceptional biology, historical RCT evidence, registry data on ASM teratogenicity, and real-world care fragmentation, a clearer picture emerges: early, high-dose folic acid is not optional add-on advice but a targeted, evidence-based standard that protects children without requiring expensive new therapies. Mainstream prenatal guidance must evolve to reflect this specificity or continue failing exactly those who need it most.